Predictive factors for poor peripheral blood stem cell mobilization and peak CD34+ cell count to guide pre-emptive or immediate rescue mobilization

被引:39
作者
Sancho, Juan-Manuel [1 ]
Morgades, Mireia [1 ]
Grifols, Joan-Ramon [2 ]
Junca, Jordi [1 ]
Guardia, Ramon [3 ]
Vives, Susana [1 ]
Ferra, Christelle [1 ]
Batlle, Monsterrat [1 ]
Ester, Anna [2 ]
Gallardo, David [3 ]
Milla, Fuensanta [1 ]
Feliu, Evarist [1 ]
Ribera, Josep-Maria [1 ]
机构
[1] Univ Autonoma Barcelona, Dept Clin Hematol, Jose Carreras Leukemia Res Inst, ICO Hosp Univ Germans Trias & Pujol, Barcelona 08916, Spain
[2] Banc Sang & Teixits, Badalona, Spain
[3] ICO Hosp Josep Trueta, Dept Hematol, Girona, Spain
关键词
lymphoma; mobilization; multiple myeloma; plerixafor; stem cell transplantation; PROGENITOR CELLS; MULTIPLE-MYELOMA; RISK-FACTORS; G-CSF; TRANSPLANTATION; FLUDARABINE; PLERIXAFOR; RECOVERY; FAILURE; HARVEST;
D O I
10.3109/14653249.2012.681042
中图分类号
Q813 [细胞工程];
学科分类号
摘要
Background aims. Failure in mobilization of peripheral blood (PB) stem cells is a frequent reason for not performing hematopoietic stem cell transplantation (HSCT). Early identification of poor mobilizers could avoid repeated attempts at mobilization, with the administration of pre-emptive rescue mobilization. Methods. Data from the first mobilization schedule of 397 patients referred consecutively for autologous HSCT between 2000 and 2010 were collected. Poor mobilization was defined as the collection of <2 x 10(6) CD34(+) cells/kg body weight (BW). Results. The median age was 53 years (range 4-70) and 228 (57%) were males. Diagnoses were multiple myeloma in 133 cases, non-Hodgkin's lymphoma in 114, acute myeloid leukemia or myelodysplastic syndrome in 81, Hodgkin's lymphoma in 42, solid tumors in 17 and acute lymphoblastic leukemia in 10. The mobilization regimen consisted of recombinant human granulocyte-colony-stimulating factor (G-CSF) in 346 patients (87%) and chemotherapy followed by G-CSF (C + G-CSF) in 51 (13%). Poor mobilization occurred in 105 patients (29%), without differences according to mobilization schedule. Diagnosis, previous therapy with purine analogs and three or more previous chemotherapy lines were predictive factors for poor mobilization. A CD34(+) cell count in PB > 13.8/mu L was enough to ensure >= 2 x 10(6) CD34(+) cells/kg, with high sensitivity (90%) and specificity (91%). Conclusions. The prevalence of poor mobilization was high, being associated with disease type, therapy with purine analogs and multiple chemotherapy regimens. The threshold of CD34(+) cell count in PB identified poor mobilizers, in whom the administration of immediate or pre-emptive plerixafor could be useful to avoid a second mobilization.
引用
收藏
页码:823 / 829
页数:7
相关论文
共 40 条
[1]   A risk-based approach to optimize autologous hematopoietic stem cell (HSC) collection with the use of plerixafor [J].
Abhyankar, S. ;
DeJarnette, S. ;
Aljitawi, O. ;
Ganguly, S. ;
Merkel, D. ;
McGuirk, J. .
BONE MARROW TRANSPLANTATION, 2012, 47 (04) :483-487
[2]   A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors [J].
Anderlini, P ;
Donato, M ;
Lauppe, MJ ;
Huh, YO ;
Martin, TG ;
Chan, KW ;
Champlin, PE ;
Körbling, M .
BRITISH JOURNAL OF HAEMATOLOGY, 2000, 109 (04) :770-772
[3]  
[Anonymous], 1996, J HEMATOTHER, V5, P213, DOI [10.1089/scd.1.1996.5.213, DOI 10.1089/SCD.1.1996.5.213]
[4]   Identification of prognostic factors for plerixafor-based hematopoietic stem cell mobilization [J].
Basak, Grzegorz W. ;
Jaksic, Ozren ;
Koristek, Zdenek ;
Mikala, Gabor ;
Mayer, Jiri ;
Masszi, Tamas ;
Labar, Boris ;
Wiktor-Jedrzejczak, Wieslaw .
AMERICAN JOURNAL OF HEMATOLOGY, 2011, 86 (07) :550-553
[5]   Haematopoietic stem cell mobilization with plerixafor and G-CSF in patients with multiple myeloma transplanted with autologous stem cells [J].
Basak, Grzegorz W. ;
Jaksic, Ozren ;
Koristek, Zdenek ;
Mikala, Gabor ;
Basic-Kinda, Sandra ;
Mayer, Jiri ;
Masszi, Tamas ;
Giebel, Sebastian ;
Labar, Boris ;
Wiktor-Jedrzejczak, Wieslaw .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2011, 86 (06) :488-495
[6]   Hematopoietic recovery in cancer patients after transplantation of autologous peripheral blood CD34+ cells or unmanipulated peripheral blood stem and progenitor cells [J].
Beguin, Y ;
Baudoux, E ;
Sautois, B ;
Fraipont, V ;
Schaaf-Lafontaine, N ;
Pereira, M ;
Paulus, JM ;
Sondag, D ;
Fillet, G .
TRANSFUSION, 1998, 38 (02) :199-208
[7]   Preferential sensitivity of hematopoietic (HPs) and mesenchymal (MPs) progenitors to fludarabine suggests impaired bone marrow niche and HP mobilization [J].
Berger, M. G. ;
Berger, J. ;
Richard, C. ;
Jeanpierre, S. ;
Nicolini, F. E. ;
Tournilhac, O. ;
Michallet, M. ;
Satta, V. M. .
LEUKEMIA, 2008, 22 (11) :2131-2134
[8]   Patients mobilizing large numbers of CD34+ cells ('super mobilizers') have improved survival in autologous stem cell transplantation for lymphoid malignancies [J].
Bolwell, B. J. ;
Pohlman, B. ;
Rybicki, L. ;
Sobecks, R. ;
Dean, R. ;
Curtis, J. ;
Andresen, S. ;
Koo, A. ;
Mineff, V. ;
Kalaycio, M. ;
Sweetenham, J. W. .
BONE MARROW TRANSPLANTATION, 2007, 40 (05) :437-441
[9]   Previous treatment predicts the efficiency of blood progenitor cell mobilisation: validation of a chemotherapy scoring system [J].
Clark, RE ;
Brammer, CG .
BONE MARROW TRANSPLANTATION, 1998, 22 (09) :859-863
[10]   Leukemic Cells Create Bone Marrow Niches That Disrupt the Behavior of Normal Hematopoietic Progenitor Cells [J].
Colmone, Angela ;
Amorim, Maria ;
Pontier, Andrea L. ;
Wang, Sheng ;
Jablonski, Elizabeth ;
Sipkins, Dorothy A. .
SCIENCE, 2008, 322 (5909) :1861-1865